



Integrum AB: Invitation to the Second Quarter 2025/26 Results Presentation

Mölnadal, Sweden – November 19, 2025 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its second quarter 2025/26 results on November 21, 2025 at 10:00 CET.

Integrum's CEO Martin Hillsten will present the report together with CFO Louise Wåhlin in a webcast. The presentation will be held in English.

Time: Friday, November 21, 2025 at 10:00 CET.

Location: Webcast (see link below).

The report will be available at <https://integrum.se/investor-relations/financial-reports-calendar/>

The webcast and presentation material will be accessible via <https://www.finwire.tv/webcast/integrum/q2-25/> where it is also possible to ask questions.

For more information, please contact:

Louise Wåhlin, CFO
Phone: + 46 (0) 734 63 73 03
E-mail: louise.wahlin@integrum.se

Certified Adviser

The Company's Certified Adviser is DNB Carnegie Investment Bank AB.

About integrum

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit <https://integrum.se/>.